Pulmonary sarcomatoid carcinoma is a rare, aggressive non-small cell lung cancer whose cells look like a sarcoma. It mostly affects older smokers, often responds poorly to chemotherapy, but frequently responds to immunotherapy or MET-targeted tablets.
What is pulmonary sarcomatoid carcinoma?
Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive type of non-small cell lung cancer. “Sarcomatoid” means that some or all of the cancer cells look like those of a sarcoma, a cancer of connective tissue, even though the tumour began in the lining cells of the lung. Under the microscope, the cells are often spindle-shaped or very large and bizarre.
PSC makes up well under 1% of lung cancers. It mainly affects older men who smoke or used to smoke. The tumours are usually large when found, often grow into the chest wall, and can spread to unusual places such as the bowel.
Compared with other non-small cell lung cancers, PSC tends to respond poorly to chemotherapy. However, two discoveries have improved the outlook for some people. Many tumours carry high levels of PD-L1, which makes them more likely to respond to immunotherapy (Hong et al., 2025). Around one in eight carries a MET exon 14 skipping change, which can be treated with targeted tablets (Mazieres et al., 2023).
1. Key facts at a glance
2. Types of pulmonary sarcomatoid carcinoma
The first three are closely related and are often grouped together. Carcinosarcoma and pulmonary blastoma are separate entities in the latest WHO classification but are still discussed under the sarcomatoid umbrella.
How PSC compares with other lung cancers
3. Causes and risk factors
Gene changes
These findings come from a systematic review of MET exon 14 skipping (Mazieres et al., 2023) and a multicentre genomic study (Hong et al., 2025).
4. How does it look
On scans
Under the microscope
Special stains
Because PSC can look like a sarcoma, mesothelioma or melanoma, pathologists use stains to confirm the diagnosis. A small biopsy may miss the sarcomatoid part, so the final diagnosis is often made on the surgical specimen.
5. Symptoms
Common symptoms
- A persistent cough
- Chest pain, especially when the tumour grows into the chest wall
- Breathlessness
- Coughing up blood
- Weight loss and loss of appetite
- Tiredness
- Fever or repeated chest infections
Symptoms of spread
When to seek medical advice
See a doctor about a cough lasting more than three weeks, coughing up blood, chest pain or unexplained weight loss, especially if you smoke or used to smoke.
6. Diagnosis
Why testing matters
Every person with advanced PSC should have their tumour tested for PD-L1 and for gene changes, ideally using a broad DNA and RNA sequencing panel. The results can be the difference between standard chemotherapy and a targeted tablet or immunotherapy. In a systematic review, MET inhibitors produced response rates of roughly 50-69% in MET exon 14-altered lung cancer as first treatment, compared with about 23-27% for chemotherapy (Mazieres et al., 2023). If there is not enough tissue, a liquid biopsy (blood test for tumour DNA) may help.
Staging
PSC is staged in the same way as other non-small cell lung cancers:
7. Treatment
Treatment is planned by a lung cancer multidisciplinary team.
Early-stage disease
In a study of 1,640 patients in the US SEER database and 175 patients from a Shanghai hospital, chemotherapy after surgery was linked with longer survival, especially in people with larger tumours or lymph node spread (Sun et al., 2020).
What to expect around lung surgery
Advanced disease
In a multicentre study of over 4,800 patients whose non-small cell lung cancer had already spread to distant sites, those with PSC did better on immunotherapy than on chemotherapy. Between 37% and 43% of PSC patients responded to immunotherapy, compared with 26-29% of those with adenocarcinoma. High PD-L1 levels appeared to explain this (Hong et al., 2025).
Side effects
8. Outlook (prognosis)
These figures come from Sun et al. (2020). Most patients in these cohorts were treated before immunotherapy and MET inhibitors became widely available, so current outcomes may be better.
Survival is linked with age, sex, tumour site, subtype, stage and treatment received. A prediction tool built on these factors performed better than stage alone (Wu et al., 2023). Early-stage disease removed with surgery has the best outlook.
Palliative and supportive care
Palliative care focuses on comfort and quality of life and can be given alongside active treatment. Teams help with breathlessness, pain, cough, tiredness and low mood. They also support families and help with planning for the future. Asking for palliative care early does not mean giving up on treatment.
9. Follow-up
10. Living with pulmonary sarcomatoid carcinoma
- Stop smoking: it improves treatment results, healing and breathing, and free support services can help
- Stay active: pulmonary rehabilitation can improve breathing and fitness
- Report new symptoms quickly, especially headaches, abdominal pain or breathlessness
- Know the signs of immunotherapy side effects, such as diarrhoea, cough or rash
- Eat well to maintain weight and strength, and ask for a dietitian referral if you are losing weight
- Have your flu and pneumococcal vaccines, as chest infections can hit harder during treatment
- Seek support from lung cancer charities, specialist nurses and palliative care teams
11. Frequently asked questions
12. Questions to ask your care team
- What subtype of PSC do I have?
- What is the stage?
- Can the tumour be removed with surgery?
- What is my PD-L1 level?
- Has the tumour been tested for MET exon 14 skipping and KRAS G12C?
- Would immunotherapy, chemotherapy or both be best for me?
- Can I be referred to pulmonary rehabilitation or palliative care?
- Am I eligible for a clinical trial?
Resources
- Hong, L. et al. (2025) ‘Distinct clinicogenomic features and immunotherapy associations in pulmonary sarcomatoid carcinoma: a multicenter retrospective study’, Journal of Thoracic Oncology, 20(12), pp. 1763-1777.
- Mazieres, J. et al. (2023) ‘MET exon 14 skipping in NSCLC: a systematic literature review of epidemiology, clinical characteristics, and outcomes’, Clinical Lung Cancer, 24(6), pp. 483-497.
- Sun, L. et al. (2020) ‘Pulmonary sarcomatoid carcinoma: experience from SEER database and Shanghai Pulmonary Hospital’, Annals of Thoracic Surgery, 110(2), pp. 406-413.
- Wu, W. et al. (2023) ‘Survival analysis and nomogram for pulmonary sarcomatoid carcinoma: an SEER analysis and external validation’, BMJ Open, 13(10), e072260.
- National Cancer Institute (2026) Non-Small Cell Lung Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.